Sichenzia Ross Ference LLP Represents Sunshine Biopharma, Inc. in $19.5 Million Private Placement Offering
Press Release – New York, NY – May 1, 2022 – Sichenzia Ross Ference LLP today announced that it represented Sunshine Biopharma, Inc., a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs (NASDAQ: SBFM), in a $19.5 million private placement. The offering included 4,862,845 units and pre-funded units at a purchase price of $4.01 per unit (or $4.009 per pre-funded unit), priced at-the-market under Nasdaq rules. Each unit and pre-funded unit consisted of one share of common stock or common stock equivalent, and two non-tradable warrants. The gross proceeds to the Company from the offering were approximately $19.5 million.
Aegis Capital Corp. acted as the Exclusive Placement Agent in connection with the offering.
The Sichenzia Ross Ference LLP team was led by partners Gregory Sichenzia, Jeff Cahlon and associate Michael Blane.
- Litigation Paralegal - November 28, 2022
- Sichenzia Ross Ference to Sponsor Gravitas Securities 6th Annual Growth Conference - November 22, 2022
- Memorandum RE: Pay v. Performance Disclosure Rules - November 22, 2022